St. Louis Park, Minnesota Clinical Trials

A listing of St. Louis Park, Minnesota clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 56 clinical trials
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during …

lung cancer
maintenance therapy
carboplatin
extensive stage sclc
solid tumour
Minnesota Oncology Hematology
 (5.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +146 other locations
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and …

lung cancer
antibody test
docetaxel
hepatitis
hiv test
Minnesota Oncology Hematology
 (5.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +97 other locations
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) …

Minnesota Oncology Hematology P.A.
 (5.3 away) Contact site
  • 0 views
  • 14 Mar, 2022
  • +227 other locations
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)

Phase 1: The investigators will conduct a prospective study to quantify the association between axillary web syndrome (AWS) and metastatic disease and chronic morbidities such as lymphedema, shoulder dysfunction, and pain comparing women (i) with AWS and (ii) without AWS in two cohorts of women. (n=200) Phase 2: This is …

lymphedema
sentinel node
breast cancer, treatment
sentinel lymph node biopsy
cancer treatment
University of Minnesota Masonic Cancer Center
 (6.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects 2 and 50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

priapism
pediatric
gene therapy
analgesia
karnofsky performance status
University of Minnesota
 (6.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (ATLAS-NEO)

This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory …

University of Minnesota Site Number : 8400016
 (6.3 away) Contact site
  • 0 views
  • 24 May, 2024
  • +53 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

lung cancer
pd-l1
platelet count
multicentric castleman disease
cisplatin
Park Nicollet Clinic - Saint Louis Park
 (1.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +358 other locations
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

rituximab
cyclophosphamide
immunochemotherapy
leukemia
monoclonal protein
University of Minnesota Masonic Cancer Center
 (6.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +2 other locations
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy …

pathologic stage iv gastric cancer ajcc v8
ct scan
definitive treatment
lymphadenopathy
chemoradiotherapy
Park Nicollet Clinic - Saint Louis Park
 (1.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +254 other locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

liquid biopsy
NTRK
systemic therapy
folic acid
pembrolizumab
Minnesota Oncology Hematology, P.A.
 (5.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +27 other locations